Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
Holding IRWD?
Track your performance easily
IRWD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.79 - $15.70
Previous Close$4.52
Volume1.31M
Average Volume (3M)2.15M
Market Cap
$722.02M
Enterprise Value$1.26B
Total Cash (Recent Filing)$105.52M
Total Debt (Recent Filing)$640.26M
Price to Earnings (P/E)104.6
Beta0.44
Next Earnings
Oct 31, 2024EPS Estimate
$0.08Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding159,739,001
10 Day Avg. Volume1,954,596
30 Day Avg. Volume2,152,227
Standard Deviation0.11
R-Squared0.05
Alpha-0.00957
Financial Highlights & Ratios
Price to Book (P/B)-2.25
Price to Sales (P/S)1.79
Price to Cash Flow (P/CF)5.40
P/FCF Ratio5.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit0.81
Enterprise Value/Ebitda-1.26
Forecast
1Y Price Target
$10.50Price Target Upside132.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Ironwood Pharma News
Bulls Say, Bears Say
Bulls Say
Commercial DynamicsApra's approval and commercial dynamics are progressing well, potentially making way for early 2026 launch.
Interest And UptakeInterest in CNP-104 is increasing.
Patient Service ProgramIRWD is starting a patient service program to drive uptake and overall compliance, while patient identification process is under way.
Bears Say
DebtThe company has a high debt load and will likely need to restructure its debt obligations within the next 2 years.
Pricing PressureLINZESS sales growth is being impacted by higher Medicaid utilization which is driving down net pricing.
Sales PerformanceLarger than expected sales declines for LINZESS are likely to remain an overhang.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $3.79 and its highest was $15.70 in the past 12 months.
What is Ironwood Pharma’s market cap?
Currently, no data Available
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Ironwood Pharma’s earnings last quarter?
Ironwood Pharma released its earnings results on Aug 08, 2024. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.156 by -$0.166.
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.29 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is $0.08.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 159,739,000 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Ironwood Pharma reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.156. Following the earnings report the stock price went down -32.612%.
Which hedge fund is a major shareholder of Ironwood Pharma?
Among the largest hedge funds holding Ironwood Pharma’s share is First Eagle Investment Management LLC. It holds Ironwood Pharma’s shares valued at 7M.
---
Ironwood Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (132.82% Upside)
$10.50 (132.82% Upside)
Blogger Sentiment
Bearish
IRWD Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 314.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $55.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-34.42%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q2 2024
0:00 / 0:00
---
IRWD Stock 12 Month Forecast
Average Price Target
$10.50
▲(132.82% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-45.67%
reiterated a buy rating last month
Copying Jason Butler's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -45.67% per trade.
---